Xanthotoxol

Xanthotoxol

SCHEMBL499269

O=c1ccc2cc3ccoc3c(O)c2o1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.59
MAOA P21397 5/20 0.59
CYP2D6 P10635 3/20 0.59
CYP1A2 P05177 3/20 0.59
CYP2C19 P33261 3/20 0.59
ACHE P22303 3/20 0.59
MAPK1 P28482 2/20 0.59
CYP2A6 P11509 2/20 0.59
TSHR P16473 1/20 0.59
PDE4A P27815 1/20 0.59
SLC6A3 Q01959 1/20 0.59
CYP2A13 Q16696 1/20 0.59
KDM4E B2RXH2 6/20 0.59
HSD17B10 Q99714 6/20 0.59
ALDH1A1 P00352 5/20 0.59
MCL1 Q07820 5/20 0.59
MAPT P10636 4/20 0.59
HPGD P15428 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
ALOX15 P16050 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30226185 0.79 CYP3A4 (0.65) CYP3A4MAOACYP2D6CYP1A2CYP2C19
SCHEMBL8416177 0.79 CYP3A4 (0.64) CYP3A4MAOACYP2D6CYP1A2CYP2C19
SCHEMBL14096644 0.78 MAOA (0.55) CYP3A4MAOACYP2D6CYP1A2CYP2C19
SCHEMBL4658019 0.77 GAA (0.75) CYP3A4CYP2D6CYP1A2CYP2C19ACHE
SCHEMBL31238062 0.77 MAOA (0.63) CYP3A4MAOACYP2D6CYP1A2CYP2C19
Daphnetin SCHEMBL128212 0.75 MCL1 (1.00) CYP3A4MAOACYP2D6CYP1A2CYP2C19
Daphnetin SCHEMBL29612544 0.75 MCL1 (1.00) CYP3A4MAOACYP2D6CYP1A2CYP2C19
Methoxsalen SCHEMBL2302069 0.75 CYP3A4 (1.00) CYP3A4MAOACYP2D6CYP1A2CYP2C19
SCHEMBL11253029 0.75 MAOA (0.59) CYP3A4MAOACYP2D6CYP1A2CYP2C19
SCHEMBL20278771 0.75 CYP3A4 (0.55) CYP3A4MAOACYP2D6CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319055-A1 COMPOSITIONS FOR TREATING GENITAL HERPES AND METHODS OF THEIR USE PAGARI LIFE SCIENCE CORP (US) 2025-10-16 US claimed
WO-2025216781-A1 COMPOSITIONS FOR TREATING GENITAL HERPES AND METHODS OF THEIR USE PAGARI LIFE SCIENCE CORP (US) 2025-10-16 WO claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 EP claimed
CN-119504904-A A natural polyphenol composition of pericarpium Citri Reticulatae Chachiensis and its preparation method 中国热带农业科学院农产品加工研究所 2025-02-25 CN claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
US-20240285660-A1 COMPOSITION FOR WOUND RELIEF AND INHIBITING A PHD PROTEIN AND METHODS OF TREATMENT CURAPEP LLC (US) 2024-08-29 US claimed
CN-116574109-A Preparation method and application of 8-hydroxy psoralen 河南中烟工业有限责任公司 2023-08-11 CN claimed
CN-116554192-A Synthesis method of 8-methoxy psoralen 河南中烟工业有限责任公司 2023-08-08 CN claimed
US-20070110851-A1 Beverage composition and method of preventing degradation of vitamins in beverages PEPSICO, INC. 2007-05-17 US claimed
EP-1782701-A1 Beverage composition and method of preventing degradation of vitamins in beverages PepsiCo, Inc. (US) 2007-05-09 EP claimed
US-20060269494-A1 New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations GUPTA SHYAM K 2006-11-30 US claimed
US-20050123636-A1 Use of the total coumarins jof cnidium monnieri in preparation of the medicament for treating psoriasis YANG LIPING (CN) 2005-06-09 US claimed
CN-1197867-C Application of fructus Cnidii total coumarin in preparation of medicine for treating psoriasis YANG LIPING (CN) 2005-04-20 CN claimed
US-20040175732-A1 Identification of micrornas and their targets NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2004-09-09 US claimed
US-20040091589-A1 Prevention of synthetic color fading in beverages using botanically derived color stabilizers PEPSICO, INC. 2004-05-13 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-5720304-A DIAGNOSIS BY CONVENTIONAL MEDICAL TECHNIQUE OR BI-DIGITAL-O-RING TEST; HAVING PATIENT INGEST ANTIBIOTIC OR ANTIVIRAL AGENT, ALSO INGEST A HERB CONCENTRATION OF UMBELLIFERAE FAMILY OVER SUSTAINED PERIOD OF TIME OMURA YOSHIAKI (US) 1998-02-24 US claimed
CN-1080537-A The goods of protect against osteoporosis and method for making thereof MEDICINE TECH DEV CENTRE ZHANJ (CN) 1994-01-12 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319055-A1 COMPOSITIONS FOR TREATING GENITAL HERPES AND METHODS OF THEIR USE TK1, TYMP, TMSB10 CYP3A4 3810/4885MAOA 1420/4885CYP2D6 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.